Evzio (autoinjector) Patent Expiration

Evzio (autoinjector) is a drug owned by Kaleo Inc. It is protected by 34 US drug patents filed from 2016 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 20, 2035. Details of Evzio (autoinjector)'s patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(10 years from now)

Active
US9517307 Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(9 years from now)

Active
US8627816 Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(7 years from now)

Active
US10143972 Ultrafiltration membrane and a preparation method thereof
May, 2031

(6 years from now)

Active
US10143792 Medicament delivery device for administration of opioid antagonists including formulations for naloxone
May, 2031

(6 years from now)

Active
US9022022 Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

Active
US9474869 Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

Active
US8939943 Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

Active
US10322239 Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

Active
US8021344 Medicament delivery device configured to produce an audible output
Nov, 2029

(5 years from now)

Active
US8226610 Medical injector with compliance tracking and monitoring
Apr, 2029

(4 years from now)

Active
US8231573 Medicament delivery device having an electronic circuit system
Nov, 2028

(4 years from now)

Active
US7749194 Devices, systems, and methods for medicament delivery
Oct, 2028

(4 years from now)

Active
US7947017 Devices, systems and methods for medicament delivery
Mar, 2028

(3 years from now)

Active
US9724471 Devices, systems, and methods for medicament delivery
May, 2027

(2 years from now)

Active
US8206360 Devices, systems and methods for medicament delivery
Feb, 2027

(2 years from now)

Active
US9238108 Medicament delivery device having an electronic circuit system
Feb, 2027

(2 years from now)

Active
US11590286 Devices, systems and methods for medicament delivery
Dec, 2026

(2 years from now)

Active
US10960155 Devices, systems and methods for medicament delivery
Jun, 2026

(1 year, 8 months from now)

Active
US7731686 Devices, systems and methods for medicament delivery
Jun, 2026

(1 year, 7 months from now)

Active
US8926594 Devices, systems and methods for medicament delivery
Mar, 2026

(1 year, 5 months from now)

Active
US9278182 Devices, systems and methods for medicament delivery
Feb, 2026

(1 year, 3 months from now)

Active
US10335549 Devices, systems and methods for medicament delivery
Apr, 2025

(6 months from now)

Active
US8016788 Devices, systems and methods for medicament delivery
Mar, 2025

(5 months from now)

Active
US7731690 Devices, systems and methods for medicament delivery
Jan, 2025

(3 months from now)

Active
US8608698 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US10314977 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US7918823 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US9737669 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US9056170 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US8361029 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US10737028 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US8425462 Devices, systems, and methods for medicament delivery
Nov, 2024

(a month from now)

Active
US8313466 Devices, systems and methods for medicament delivery
Nov, 2024

(a month from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Evzio (autoinjector)'s patents.

Given below is the list of recent legal activities going on the following patents of Evzio (autoinjector).

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jun, 2024 US9517307
Payment of Maintenance Fee, 12th Year, Large Entity 20 May, 2024 US8313466
Payment of Maintenance Fee, 8th Year, Large Entity 25 Apr, 2024 US9474869
Maintenance Fee Reminder Mailed 01 Apr, 2024 US10737028
Payment of Maintenance Fee, 12th Year, Large Entity 31 Jan, 2024 US8231573
Payment of Maintenance Fee, 12th Year, Large Entity 24 Jan, 2024 US8226610
Payment of Maintenance Fee, 12th Year, Large Entity 26 Dec, 2023 US8206360
7.5 yr surcharge - late pmt w/in 6 mo, Large Entity 13 Dec, 2023 US9278182
Payment of Maintenance Fee, 8th Year, Large Entity 13 Dec, 2023 US9278182
Maintenance Fee Reminder Mailed 30 Oct, 2023 US9278182

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Evzio (autoinjector) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Evzio (autoinjector)'s family patents as well as insights into ongoing legal events on those patents.

Evzio (autoinjector)'s Family Patents

Evzio (autoinjector) has patent protection in a total of 15 countries. It's US patent count contributes only to 49.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Evzio (autoinjector).

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Evzio (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 20, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Evzio (autoinjector) Generics:

Naloxone Hydrochloride is the generic name for the brand Evzio (autoinjector). 29 different companies have already filed for the generic of Evzio (autoinjector), with Igi Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Evzio (autoinjector)'s generic

Alternative Brands for Evzio (autoinjector)

Evzio (autoinjector) which is used for reversing opioid overdose., has several other brand drugs in the same treatment category and using the same active ingredient (Naloxone Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Kaleo Inc
Evzio

(uses Naloxone Hydrochloride)

Used for opioid overdose reversal.
Auvi-q used for treating severe allergic reactions in patients with a weight between 7.5 to 15 kg.
Naloxone Hydrochloride (autoinjector)

(uses Naloxone Hydrochloride)

Used for reversing opioid overdose.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Naloxone Hydrochloride. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Bdsi
Bunavail
Emergent
Narcan
Harm Reduction Therp
Rivive
Hikma
Kloxxado
Indivior
Suboxone
Orexo Us Inc
Zubsolv
Purdue Pharma Lp
Targiniq
Zmi Pharma
Zimhi


Apart from brand drugs containing the same ingredient, some generics have also been filed for Naloxone Hydrochloride, Evzio (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Evzio (autoinjector)





About Evzio (autoinjector)

Evzio (Autoinjector) is a drug owned by Kaleo Inc. It is used for reversing opioid overdose. Evzio (Autoinjector) uses Naloxone Hydrochloride as an active ingredient. Evzio (Autoinjector) was launched by Kaleo Inc in 2016.

Approval Date:

Evzio (autoinjector) was approved by FDA for market use on 19 October, 2016.

Active Ingredient:

Evzio (autoinjector) uses Naloxone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Naloxone Hydrochloride ingredient

Treatment:

Evzio (autoinjector) is used for reversing opioid overdose.

Dosage:

Evzio (autoinjector) is available in solution form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
2MG/0.4ML (2MG/0.4ML) SOLUTION Discontinued INTRAMUSCULAR, SUBCUTANEOUS